The shares of Dishman Carbogen Amcis Limited, a Contract Research, and Manufacturing Services (CRAMS) provider, opened at Rs 109.30 levels only to gain as much as 13 percent to reach an intra-day high of Rs 124.40 on Tuesday.
After posting its December quarter results, the stock has gained as much as 40 percent in just 8 trading sessions. The company in the period reported a 14 percent increase in revenue, which stood at Rs 639.79 Crore in Q3FY23 compared to Rs 562.08 Crore Year on Year.
In the previous quarter, their revenue was Rs 613.96 Crore. Their revenue increased across all segments due to strong demand and a healthy order book.
Their bottom line stood at Rs 46.96 Crore in the quarter under review to a loss of Rs 10.05 Crore in the September quarter. On a YoY basis, their profits jumped by 33 percent from Rs 35.38 Crore.
Dishman Carbogen Amcis Ltd provides Contract Research and Manufacturing Services (CRAMS) as well as the production and distribution of marketable molecules such as specialty chemicals, vitamins and chemicals, and disinfectants. It operates in India, Switzerland, the United Kingdom, France, China, and the Netherlands.
Its French subsidiary, CARBOGEN AMCIS opened a new state-of-the-art facility dedicated to sterile liquid drug product manufacturing in Saint- Beauzire, France. This was made with an investment of $50 million. The company successfully completed a routine U.S. Food and Drug Administration (FDA) inspection without any major or critical observations.
The small-cap stock with a market capitalization of Rs 1,882 Crores forms part of not one but two Ace investors of India. Mukul Mahavir Agrawal holds 55,00,000 shares or a 3.51% stake with a holding value of Rs 67.5 Crore. Meanwhile, Rekha Jhunjhunwala holds 25,50,000 shares or a 1.6% stake with a holding value of Rs 30.7 Crore.
Written by Anoushka Roy
